Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
J Rheumatol ; 36(9): 2114-21, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19738223

ABSTRACT

There is great concern about clearly defining benefit and risk in the context of both drug development and clinical practice. In view of this pressure, the OMERACT Executive identified the need to bring together clinical trialists, pharmacoepidemiologists, clinicians, clinical epidemiologists, statistical experts, and regulatory representatives to discuss different approaches to define risk and perhaps improved ways to express it. Each attendee spoke on a given topic and the group was charged to consider the issue of risk in the context of formally posed questions. This article provides a summary of the presentations and outlines the discussions that followed.


Subject(s)
Antirheumatic Agents/therapeutic use , Drug-Related Side Effects and Adverse Reactions , Rheumatic Diseases/drug therapy , Antirheumatic Agents/adverse effects , Biomedical Research , Humans , Pharmacoepidemiology , Product Surveillance, Postmarketing , Randomized Controlled Trials as Topic , Registries , Risk Assessment
SELECTION OF CITATIONS
SEARCH DETAIL
...